Salvo Health: Travelocity and Foursquare Exec Jeff Glueck Has Raised $10.5M to Disrupt the GI Health Market

Podcast: Play in new window | Download (Duration: 30:22 — 41.7MB)

Subscribe: Spotify | iHeartRadio | Email | Deezer | RSS | More

In health innovation – which is the world we inhabit at StartUp Health – there are certain issues that get the lion’s share of attention. Think wearables for tracking daily activity or new mental health solutions. A lot of attention is going towards interventions for seniors and addressing issues of loneliness and isolation. These are wonderful areas of development. But there are other areas of health that have huge implications across society, yet have a way of flying under the radar. There’s stigma – like our hesitance to talk about mental health struggles – and then there’s society’s reaction to gastrointestinal conditions. GI problems. Irritable bowel syndrome or IBS. Celiac disease. The list goes on. Each year, 62 million Americans are diagnosed with a digestive disorder. Another 30 million go undiagnosed. They’re often too embarrassed to even talk to their primary care provider about it, so they suffer in silence, and it has negative ripple effects across their entire life.

Well, all that seems to be about to change. The virtual healthcare revolution has reached the GI market with the launch of Salvo Health, a company that’s using virtual care to bring the best gut health tools and therapies to millions of people.

Heading up the effort is CEO and Co-founder Jeff Glueck, who is our guest on today’s episode. Jeff is a tech industry veteran, having been Chief Marketing Officer at Travelocity during their meteoric rise, and the CEO of the social app Foursquare. He’s leveraging that experience to disrupt an old school industry and bring relief to millions. The company, which joined StartUp Health last year, has just announced a $10.5M Seed raise to bring Salvo out of stealth mode and start to scale in earnest.

How’s Jeff going to use his experience at Travelocity and Foursquare to disrupt the GI health market? We’ll let him explain in the interview.